The Pharmaceutical Code Company acquires The CQA Company™, TCTC Asia and TCTC ANZ and will now be known as Acceler8 Clinical Research.
The Pharmaceutical Code Company LTD (TPCC) is delighted to announce the acquisition of The CQA Company™, The CLINICAL TRIAL Company (ASIA) Pte. Ltd and The CLINICAL TRIAL Company (ANZ) Pte. Ltd, all formerly part of UK headquartered TCTC Group. The acquisition expands the service offering and global reach of The Pharmaceutical Code Company. The new group will be known as Acceler8 Clinical Research, helping to accelerate all areas of their customers’ clinical research requirements.
The CQA Company™ has delivered clinical quality assurance services, globally, since 2002. Thomas Richardson, General Manager of Acceler8 Clinical Research commented “The CQA Company are a trusted QA partner for leading pharmaceutical companies and biotechs around the world and will be a great asset to our company both internally, and for our valued customers. Our excellent global team of high-quality QA experts will continue to give our clients the absolute highest level of service for all their quality needs, for many years to come”. He went on to add: “I am thrilled that under the new name of Acceler8 Clinical Research, I will be leading a highly-skilled global team of clinical research professionals who keep the patients and our customers at the heart of everything we do to ensure that we keep accelerating our customers’ products to market well into this decade and beyond.”
Both formerly divisions of TCTC Group, delivering full-service clinical research support since 2002, TCTC (ANZ) and TCTC (Asia) will now be known as Acceler8 Clinical Research (Asia) and Acceler8 Clinical Research (ANZ) respectively. Services include Project Management, Data Management, Quality Assurance, Regulatory Affairs and Clinical Operations. Strategically situated at the heart of South East Asia, Acceler8 ASIA has its headquarters in Singapore. The accelerated growth of Singapore makes this the ideal location to partner with clients working to deliver their pipeline in one of the most booming clinical trial regions in the world. Meanwhile, Acceler8 Australia’s headquarters in Melbourne provide a strong local presence in one of Australia’s largest and fastest growing cities, while also facilitating the delivery of services to a wider network of partners across Australia and New Zealand.
Following the acquisitions, The Pharmaceutical Code Company now offers all services under the trading name ‘Acceler8 Clinical Research’. Executive Director, Kerri Leeming added ‘this marks an exciting new era for The Pharmaceutical Code Company. We have a pragmatic, experienced and innovative team, dedicated to providing exemplary customer service for our clients. I look forward to assisting our customers and moving the pharmaceutical industry forwards together under our new global brand.”
About The Pharmaceutical Code Company
The Pharmaceutical Code Company is a privately owned, full-service contract research organisation, formed in 2008 helping pharmaceutical manufacturers and research organisations to comply with regulations, adhere to ICH GCP, and successfully bring their products to market.
Accler8™ Clinical Research
Mere View Barn